PI4K2A Antibody
Description
Introduction
The PI4K2A antibody is a critical research tool for studying phosphatidylinositol 4-kinase type 2-alpha (PI4K2A), a lipid kinase essential for cellular processes such as membrane trafficking, signaling, and organelle function. This enzyme catalyzes the phosphorylation of phosphatidylinositol (PI) to phosphatidylinositol 4-phosphate (PI4P), a precursor for other phosphoinositides that regulate cellular homeostasis . The antibody enables detection and functional analysis of PI4K2A in various experimental contexts, including Western blotting (WB), immunofluorescence (IF), and immunohistochemistry (IHC).
Key Features of PI4K2A Antibodies
PI4K2A antibodies are available in multiple formats, each optimized for specific applications:
These antibodies target distinct regions of PI4K2A, such as the N-terminal (1–30 aa) or internal sequences (131–479 aa) , ensuring specificity.
Applications in Research
PI4K2A antibodies have been instrumental in elucidating the enzyme’s roles in:
-
Lung Cancer: PI4K2A promotes tumor growth by stabilizing EGFR and facilitating vesicular trafficking of oncogenic proteins . Antibodies have shown that PI4K2A depletion inhibits cancer progression by disrupting secretory pathways .
-
Neurodegeneration: Gene-trap mice lacking PI4K2A exhibit delayed neurodegeneration, linked to defective lysosomal repair mechanisms . Antibodies localized PI4K2A to lysosomal membranes during damage .
-
Lysosomal Quality Control: PI4K2A is activated during lysosomal membrane damage, initiating repair via ER-lysosome contacts . Antibodies confirmed its recruitment to damaged lysosomes .
Research Insights
-
Therapeutic Potential: PI4K2A inhibitors are being explored for cancer treatment, particularly in KRAS-driven tumors, where combined PI4K2A/PI3K inhibition shows synergy .
-
Post-Translational Modifications: Palmitoylation at the CCPCC motif is critical for PI4K2A’s Golgi localization . Antibodies have visualized this lipid modification in cellular models .
Product Specs
Target Background
- PI-273, the first substrate-competitive, subtype-specific inhibitor of PI4KIIalpha, facilitates the evaluation of PI4KIIalpha as a potential cancer therapeutic target. PMID: 28827373
- Analysis of oncogenomic databases reveals a correlation between loss of the PI4K2B allele and underexpression of PI4KIIbeta mRNA with human cancers. This finding aligns with cellular data and suggests that PI4KIIbeta could function as a clinically significant suppressor of invasion. PMID: 27798239
- PtdIns4KIIalpha regulates receptor sorting at early endosomes through a PtdIns(4)P-dependent pathway and contributes to the synthesis of endosomal PtdIns(4,5)P2. PMID: 26823017
- PI4KIIalpha serves as a specific downstream effector of GABARAP and generates PI4P, which plays a key role in the final stage of autophagy. PMID: 26038556
- Knockdown of phosphatidylinositol 4-kinase IIalpha inhibits vesicle-associated membrane protein 3 (VAMP3) trafficking to perinuclear membranes and impairs the rate of VAMP3-mediated recycling of the transferrin receptor. PMID: 25002402
- Structural and phylogenetic analysis of PI4KIIalpha has been conducted. PMID: 24752359
- PI4K2A acts as a novel regulator of vesicular trafficking and neurotransmission in the brain. PMID: 25083612
- The palmitoylation insertion contributes to the phosphatidylinositol-binding pocket and anchors PI4KIIalpha to the membrane. PMID: 24675427
- The Hermansky-Pudlak syndrome complex BLOC-1 and its cargo PI4KIIalpha interact with regulators of the actin cytoskeleton. PMID: 23676666
- Knockdown of PI4KIIalpha inhibits EGF-stimulated Akt phosphorylation. PMID: 21218173
- Research suggests that the phosphatidylinositol 4-kinase 2-alpha gene may not be the cause of autosomal recessive hereditary spastic paraplegia in humans. PMID: 21190509
- PI4KIIalpha acts as a novel regulator of tumor growth through its effects on angiogenesis and HIF-1alpha regulation. PMID: 20154717
- The T cell antigen CD7 is associated with type II phosphatidylinositol-4 kinase, a key component in inositol phosphate turnover pathways. PMID: 12594831
- The active site of PI4KIIalpha is found in a p97/valosin-containing-protein-rich fraction of the endoplasmic reticulum. PMID: 12650639
- PI4KIIalpha generates PI(4)P-rich domains that specify the docking of the AP-1 coat machinery, contributing to the unique lipid-defined organelle identity of the Golgi apparatus. PMID: 12914695
- The linkage of CD63 with PI 4-kinase type II may lead to the recruitment of this signaling enzyme to specific membrane locations in the platelet, influencing phosphoinositide-dependent signaling and platelet spreading. PMID: 15711748
- Changes in the membrane environment can regulate PI4KIIalpha activity. PMID: 16249177
- Phosphatidylinositol 4-kinase IIalpha is essential for the correct endocytic traffic and downregulation of activated epidermal growth factor receptor. PMID: 16443754
- Both the kinase activity and the sorting signal present in PI4KIIalpha are necessary to rescue endosomal PI4KIIalpha siRNA-induced mutant phenotypes. PMID: 18256276
- AP-3 and BLOC-1 work together, either concurrently or sequentially, to specify the sorting of PI4KIIalpha along the endocytic route. PMID: 19010779
- Dvl directly interacts with and activates PI4KII alpha, increasing its V(max) for ATP and PtdIns. Additionally, Dvl regulates PI4KII alpha and PIP5KI through different domains. PMID: 19561074
